Literature DB >> 1706302

Malignant mixed müllerian tumors: an immunohistochemical study of 47 cases, with histogenetic considerations and clinical correlation.

E George1, J C Manivel, L P Dehner, M R Wick.   

Abstract

Forty-seven cases of malignant mixed müllerian tumors were reviewed histologically and studied immunohistochemically with three major objectives: to analyze the histogenetic relationship between the carcinomatous and sarcomatous components of these neoplasms, to ascertain the practical role of immunohistochemical studies in diagnosis and classification, and to determine the prognostic significance of immunohistochemically verified rhabdomyoblastic and neuroendocrine differentiation. Epithelial differentiation (cytokeratin and/or epithelial membrane antigen expression) was confirmed in all carcinomatous components; within the sarcomatous areas, it was identified among individual cells (60% of cases) and within poorly formed clusters of cells (57% of cases). There was a statistically significant tendency for concordant expression of alpha-1-antichymotrypsin, Leu-M1, S-100, Leu-7, and neuron-specific enolase between the carcinomatous and sarcomatous components of individual cases. These two findings provide evidence of common origin for the sarcomatous and carcinomatous components of these neoplasms. Histologic review of metastases in 21 cases revealed a biphasic composition in the majority of metastatic lesions (62%), another feature that further supports a common origin for the two components. From a practical standpoint, immunohistochemistry may be helpful in accentuating the biphasic pattern of these neoplasms and in verifying the presence of rhabdomyoblastic differentiation. In most cases, however, careful morphologic examination and thorough sampling will suffice for correct diagnosis and subclassification. The presence of heterologous, rhabdomyoblastic, or neuroendocrine differentiation did not have a statistically significant influence on survival; the last of these was associated with a tendency for a more rapidly fatal course.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1706302     DOI: 10.1016/0046-8177(91)90153-g

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  16 in total

Review 1.  Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs): Unifying the Concept of a Heterogeneous Group of Neoplasms.

Authors:  Stefano La Rosa; Fausto Sessa; Silvia Uccella
Journal:  Endocr Pathol       Date:  2016-12       Impact factor: 3.943

2.  A mixed mesodermal tumor of the cecum: report of a case.

Authors:  A Shimizu; K Ohno; Y Masuda; F Endou; Y Masuda; A Ogata; M Nagai; G Obata; K Asano
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

Review 3.  Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?

Authors:  W G McCluggage
Journal:  J Clin Pathol       Date:  2002-05       Impact factor: 3.411

4.  Paclitaxel-carboplatin for advanced or recurrent carcinosarcoma of the uterus: the Japan Uterine Sarcoma Group and Tohoku Gynecologic Cancer Unit Study.

Authors:  Tadao Takano; Takeo Otsuki; Hideki Tokunaga; Masafumi Toyoshima; Hiroki Utsunomiya; Satoru Nagase; Hitoshi Niikura; Kiyoshi Ito; Nobuo Yaegashi; Hidekazu Yamada; Toru Tase; Masahiro Kagabu; Tadahiro Shoji; Toru Sugiyama; Naoki Sato; Toshio Fujimoto; Yukihiro Terada; Kenji Nakahara; Hirohisa Kurachi; Yoshihito Yokoyama; Hideki Mizunuma; Shu Soeda; Hiroshi Nishiyama; Takashi Matsumoto; Shinya Sato; Muneaki Shimada; Junzo Kigawa
Journal:  Int J Clin Oncol       Date:  2014-01-07       Impact factor: 3.402

5.  Malignant Mixed Mullerian Tumor of the Extra-genital Coelomic Epithelium: Report of Two Cases.

Authors:  Irene G Ibanez-Manlapaz; David Mc Coy; Vincent Vincent; Ulla Jo Ule
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

Review 6.  Ovarian teratoid carcinosarcoma with a PIK3CA mutation: a case report and review of the literature.

Authors:  Masato Aoki; Hisamitsu Takaya; Tomoyuki Otani; Hidekatsu Nakai; Kosuke Murakami; Noriomi Matsumura
Journal:  Int Cancer Conf J       Date:  2022-08-08

Review 7.  Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma.

Authors:  T S Shylasree; Andrew Bryant; Ram Athavale
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

8.  Molecular genetic aberrations of ovarian and uterine carcinosarcomas--a CGH and FISH study.

Authors:  Alexander Schipf; Doris Mayr; Thomas Kirchner; Joachim Diebold
Journal:  Virchows Arch       Date:  2008-03       Impact factor: 4.064

Review 9.  Primary malignant mixed Müllerian tumour (MMMT) of the vagina and review of the literature.

Authors:  Geetha Visvalingam; Wai Kheong Ryan Lee; Chin Fong Wong; Yong Kuei Lim
Journal:  BMJ Case Rep       Date:  2016-04-25

10.  Role of TGF-β signaling in uterine carcinosarcoma.

Authors:  Shailendra Kumar Dhar Dwivedi; Scott D McMeekin; Katrina Slaughter; Resham Bhattacharya
Journal:  Oncotarget       Date:  2015-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.